Head-To-Head Survey: Novo Nordisk A/S (NYSE:NVO) and Relmada Therapeutics (NASDAQ:RLMD)

Relmada Therapeutics (NASDAQ:RLMD) and Novo Nordisk A/S (NYSE:NVO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Relmada Therapeutics and Novo Nordisk A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-71.22%	-64.46%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Earnings & Valuation

This table compares Relmada Therapeutics and Novo Nordisk A/S”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38 million	($1.09)	-4.93
Novo Nordisk A/S	$46.80 billion	4.38	$15.51 billion	$4.09	11.22

Novo Nordisk A/S has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Relmada Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Novo Nordisk A/S has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Relmada Therapeutics and Novo Nordisk A/S, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1	1	5	1	2.75
Novo Nordisk A/S	1	15	5	0	2.19

Relmada Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 123.46%. Novo Nordisk A/S has a consensus target price of $65.81, suggesting a potential upside of 43.37%. Given Relmada Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Relmada Therapeutics is more favorable than Novo Nordisk A/S.

Insider & Institutional Ownership

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Relmada Therapeutics on 8 of the 13 factors compared between the two stocks.

About Relmada Therapeutics

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.